Objectives: Vitamin D deficiency and Chronic Obstructive Pulmonary Disease (COPD) are both under-recognized health problems, world-wide. Although Vitamin D has long been known for calcemic effects it also has less known noncalcemic effects. Recent data have shown that Vitamin D deficiency is highly prevalent in patients with COPD and correlates with forced expiratory volume in one second (FEV 1 ) and FEV 1 decline. The objective of this work was to review the current literature on vitamin D deficiency in relation with COPD.
Results: The noncalcemic effects of vitamin D relating with COPD may be summarised as increasing antimicrobial peptide production, regulation of inflammatory response and airway remodelling. Vitamin D inhibits the production of several proinflammatory cytokines and leads to suppression Th1 and Th17 responses which may be involved in the pathogenesis of COPD. Vitamin D insufficiency may also contribute to chronic respiratory infections and airway colonization so returning vitamin D concentrations to an optimal range in patients with COPD might reduce bacterial load and concomitant exacerbations.Vitamin D is also important for COPD-related comorbodities such as osteoporosis, muscle weakness and cardiovascular diseases. Data about the effect of Vitamin D supplementation on those comorbidities in relation with COPD are been scarce.
Conclusion:
Improving the blood level of Vitamin D into the desired range may have a beneficial effect bones and muscles, but more studies are needed to test to test that hypothesis.
as "Morbus Anglorum". The association between inadequate sunshine and rickets was first recognized in the beginning of the 20th century. 6, 7 More recently there has been increased interest in vitamin D regarding its potential noncalcemic effects and its relationship with chronic disease, particularly COPD. There might be a possible link between vitamin D hypovitaminosis and COPD pathogenesis, progression, exacerbations and comorbidities. This raised the question as to whether vitamin D supplementation might be beneficial in COPD. This paper reviews the currently available evidence.
| Vitamin D synthesis and metabolism
Under the ultraviolet B (290-315 nm) [UV-B] irradiation, vitamin D is synthesised in the skin as previtamin D3, which is converted to vitamin D3, also known as cholecalciferol. The efficiency of conversion of the previtamin to vitamin D3 depends on the number of the UV-B photons and the degree of skin melanin pigmentation. An increase in melanin, skin cover with sunscreen or excessive clothing reduces vitamin D3 production. Excessive sunlight exposure does not cause vitamin D3 intoxication because sunlight destroys any excess vitamin D3 in skin. 6, 8 Vitamin D2 (known as ergocalciferol and obtained by irradiation of plants or food) and vitamin D3 (supplied by fortified food, diet supplement and fish e.g., herring and mackerel) are integrated into chylomicrons and absorbed through the lymphatic system. In the blood, it is carried by vitamin D Binding Protein (DBP) to the liver where it is hydroxylated to form 25-hydroxyvitamin D (25 (OH) D). This is the major form of vitamin D and is used as a measure of vitamin D status in the body. In the kidney, 2 D are the small intestine, kidney and bones 6, 8 ( Figure 1 ).
In vitamin D deficiency, calcium and phosphorus absorption from the small intestine is impaired and only 10% of calcium and 50% of phosphorus can be absorbed. This results in an increase in parathyroid hormone (PTH) which stimulates the reabsorption of calcium in the kidney to preserve blood calcium level. PTH also inhibits the reabsorption of phosphorus resulting in increased urinary excretion. Hence, PTH stimulates osteoclasts to mobilize skeletal calcium to the blood in order to keep calcium level in steady. In secondary hyperparathyroidism, PTH stimulates the kidney to produce 1,25-(OH) 2 D so that the level of 1,25-(OH) 2 D may be high or normal which means that it is unreliable marker of the status of vitamin D needs of the body. Eventually, vitamin D deficiency causes impairment of mineralization of the skeleton resulting in rickets in children. However, vitamin D deficiency can be subclinical and accompanied by normal serum calcium levels, low 25(OH)-D level (10-20 ng/mL), high PTH, 1,25-(OH) 2 D and alkaline phosphatase levels 8 ( Figure 1 ).
| Definition of vitamin D deficiency
The level of vitamin D deficiency depends on the cut points of 25(OH) D levels. A serum level of 10 ng/mL (25 nmol/L) of 25(OH) D is considered to be the threshold for preventing rickets and osteomalacia, but the desirable level to suppress PTH activity and for many other essential noncalcemic health benefit should be above 20-30 ng/mL. [9] [10] [11] In a study carried out in indoor office workers who reside in subtropical climate if the cut point was chosen as 50 nmol/L (20 ng/mL), the number of vitamin D sufficient people were 60% however if the cut point was increased to 75 nmol/L (30 ng/L), this number reduced to 13%.
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The US Endocrinology Society defined vitamin D deficiency as a blood 25(OH) D level below 20 ng/mL (50 nmol/L) and vitamin D insufficiency when the level lies between 21 and 29 ng/mL (52.5-72.5 nmol/L). 30 ng/mL is considered as desirable blood level. In the absence of adequate sun exposure, at least 800-1000 IU vitamin D per day may be needed to maintain 30 ng/mL blood level of vitamin D. 9, 10, 13 The response to vitamin D supplementation may vary individually. Recent data showed that patient's baseline vitamin D level and the amount of supplementation were the most accountable factors in response however, genetic variability may be associated with response to supplementation, suggesting that some people might need higher doses to reach optimal 25(OH) D levels or that there is variability in the physiologically normal level of 25(OH) D. 14 
| Risk factors for vitamin D deficiency
Vitamin D deficiency is mostly caused by inadequate exposure to sunlight and inadequate dietary intake. Natural nutritional sources are mainly limited to fatty fish, so regular sunlight exposure is still the best way to prevent and resolve vitamin D deficiency. To have appropriate vitamin D3 production, direct sunlight exposure needs to be maintained for only 15 minutes twice a week (without wearing sunscreen).
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Since there is a seasonal variation in sunlight, there is also a seasonal variation in serum vitamin D level which shows the highest level in summer and the lowest level in winter in the northern hemisphere. [16] [17] [18] Even during the summer, early morning and late afternoon UV-B is not sufficient to activate vitamin D production in the skin. 19 Hence, people who live in higher latitude have a higher risk of vitamin D deficiency. Premenopausal women have been shown to have 6 nmol/L higher serum levels compared to postmenopausal women. 19 Apart from sun exposure and skin vitamin D synthesizing ability, premature birth, pigmented skin, obesity, malabsorption, glucocorticoid usage, smoking, advanced age, and reduced physical activity are also risk factors for vitamin D deficiency which most of them are also risk factors for COPD.
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| E PIDEM I OLO GY
Vitamin D deficiency is under diagnosed. Depending on which cut off has been used, 57%-93% of the general inpatient population was defined as deficient. 16, 18 In hip fractured elderly patients, vitamin D level was detected under 20 nmol/L in 80% of the people. 19 In a review by Lips, in which vitamin D deficiency was defined when serum 25(OH)D was lower than 25 nmol/L (10 ng/mL) and vitamin D insufficiency was considered when serum 25(OH)D was between 25 and 50 nmol/L (10-20 ng/mL), the prevalence of deficiency was reported to be between 2% and 30% of adults in European countries. In Germany, in people aged between 50 and 81 years, the prevalence of deficiency was 25%. In postmenauposal women, in Italy, the prevalence was 28%-32%.
authors concluded that it was related with clothing habit. 27 Adults living in urban, non-coastal setting also had a high prevalence of vitamin D deficiency. ( Figures 2 and 3 ). Genetic defects in VDR and vitamin D-binding protein (VDBP) may produce a situation like vitamin D deficiency. VDBP is also known as Gc-globulin and located in various body fluid and many cell surfaces including human neutrophils. VDBP has three domains that have a lot of additional functions besides carrying vitamin D, especially in macrophage and neutrophils. 37 These include the augmentation of chemotactic response to complement anaphylatoxin C5a and formation of a dimeric molecule with macrophage activating factor (DBP-MAF) which changes macrophages to more phagocytic phenotype. 38 The VDBP gene is highly polymorphic. There are three common variants Gc1F, Gc1S, Gc2. These variations may have a role in the pathogenesis of lung diseases including asthma, COPD, lung cancer, tuberculosis, respiratory syncytial virus (RSV) bronchiolitis, and adult respiratory distress syndrome. 37, 39 Several polymorphisms have been shown in the VDR gene too and there are data showing a relationship between VDR gene polymorphism and tuberculosis and RSV infections. 15 
| Noncalcemic effects of vitamin D deficiency
It has been shown that VDR and VDBP are present, not only in the organs associated with calcium metabolism but also in some other essential organs, such as skeletal muscle, lung, brain, immune cells including monocytes, activated macrophages, dendritic cells, natural killer cells, and T and B cells, pancreas, breast, colon and heart. 8, 15 36 function in adults, a serum level above 30 ng/mL is required. In a study performed on both active and inactive people over 60 years of age, showed that a vitamin D level in the range 40-94 nmol/L was best for good musculoskeletal function in the legs. 40 Vitamin D deficiency has been shown to be associated with breast, colon, prostate, ovary and esophagus cancers, although it is not known whether maternal, in utero or childhood deficiency increases the future risk of cancers. Children exposed to sunlight have been shown to have 40% less risk of developing non-Hodgkin lymphoma and have better survival from malignant melanoma. 8 In a prospective US cohort, it was estimated that for every 10 ng/mL increase in serum vitamin D there was a 17% reduction in overall cancer rate and 45% reduction in gastrointestinal cancers. 41 The risk of developing multiple sclerosis is 50% greater when the vitamin D level is below 20 ng/mL. 35 Living at high latitude for the first 10 years of life is associated with a doubling of the risk of developing multiple sclerosis, no matter where people live after that. 35 Children living in higher latitudes are more prone to developing Type I diabetes, supplementation of vitamin D can reduce that risk. 42 
| Vitamin D deficiency and COPD
Vitamin D deficiency is highly prevalent in chronic lung disease, but the mechanism linking the two has not been fully elucidated. Animal and laboratory studies showed substantial positive effects of vitamin D on the alveolar type II cell, fibroblast proliferation, surfactant synthesis, and alveolarization. 45 Vitamin D deficiency has been shown to be more prevalent in impaired fetal lung size, childhood asthma, cystic fibrosis, respiratory infections, tuberculosis, COPD, and diffuse parenchymal lung disease 10, 36, 46 ( Figure 3 ).
The recent Western Australian Birth Cohort study showed that, 36% of the pregnant women had vitamin D deficiency and after adjusting other confounders, vitamin D deficiency is related with lung impairment in 6-year-old offspring. 47 Additionally, in a longitudinal study, low maternal Vitamin D level was found to be associated with asthma in the first 10 year of children. 48 The causal mechanisms in these associations are not clearly known. Immune mechanisms and the possible effects on smooth muscle cell proliferation and differentiation and lung growth may cause these associations. 49, 50 Low birth weight is also shown to be related with the development of COPD. 51 An age-matched controlled study showed that COPD patients had significantly lower vitamin D levels when compared to controls, which might suggest that COPD patients have a higher risk of vitamin D deficiency. 10, 35 This could be due to low food intake, aging, staying indoors, increased vitamin D catabolism due to glucocorticosteroids, impaired activation by renal dysfunction, lower storage capacity in muscles or fat tissues due to wasting.
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| The role of vitamin D in COPD onset
Numerous genetic and immunologic studies have been performed to investigate test for a causal relationship between vitamin D and the development COPD. There is evidence that Th1 immunity and Th17 are involved in COPD and may provide a link between vitamin D deficiency and COPD. 35 Deficiency might enhance inflammation, parenchymal degradation, IL-18, TNF-a, Matrix Metalloproteinase (MMP)-9 productions, chemokine productions (through NF-ƘB), histone acetylation and corticosteroid resistance. Vitamin D also has a role in airway smooth muscle remodelling 36, 53 ( Figure 3 ).
In genetic research, certain allelic mutations in VDBP may either increase the risk or have a protective effect for developing COPD. Ethnicity may be an important factor. For instance, in many small studies, in Caucasians, Gc2 protein was found to be protective against COPD, however, in an Asian population presence of the Gc1F variant was a risk factor for COPD. 39, 54 Studies regarding different VDBP variants and their effects on the development of COPD are summarised at Table 1 . 37 It is very challenging to dissect out the effect of vitamin D from VDBP itself, since most of the actions of VDBP are thought to be through enhancing the bioavailability of the active vitamin D metabolite. In a recent very large general population study, 10 116 participants from Copenhagen City Heart Study and 8391 participants from Copenhagen General Population Study were studied to test if a low plasma level of 25 (OH) D was associated with future risk of COPD. It found an association; hazard ratio: 1.58 and 2.00 for the two studies respectively. 55 In a very recent Danish study performed in 12 041 individuals with an average of 9.7-year follow-up, a statistically significant inverse crosssectional association was found between vitamin D status and prevalent COPD but not with incident COPD. 44 
| Calcemic effects in COPD
In the National Health and Nutrition Examination Survey (NHANES) III study, in 9502 participants, airflow limitation was independently associated with an increased odds ratio (OR) for osteoporosis (OR: 1.9). In severe airflow obstruction, this OR reached 2.4 and the observation was true for both women and men. The study highlighted that, in moderate to severe COPD, osteoporosis should be actively sought. 56 In Towards a Revolution in COPD Health Study (TORCH) in a post hoc analysis conducted in 658 patients, almost 50% of the patients had osteoporosis or osteopenia regardless of sex. 57 Currently the overall prevalence of osteoporosis defined by low bone mineral density was 35.1% on average, ranging from 8.7% to 69% more occurred in ill patients and patients with exacerbation. As a consequence, prevalence of morphometric vertebral fractures in COPD patients has been reported to be 24%-79%. 58 Osteoporosis could be related with many parameters of lung functions. In a study performed in 49 COPD patients, patients with osteoporosis had a significantly lower (BMI) and higher residual volume (RV) as the percentage of total lung capacity (RV%TLC) compared to COPD patients without osteoporosis. 59 Osteoporosis in COPD may result from several conditions that eventually ended up with vitamin D deficiency and bone resorption. People with COPD tend to be older, physically less active, more home-bounded and with less muscle bulk, which all result in less vitamin D production. As a major cause of osteoporosis, vitamin D deficiency should be checked in COPD actively, and replacement therapy should be considered in patients who are deficient. Remarkable number of human studies have indicated the clinical association of vitamin D deficiency and respiratory infections. In a Finnish study, conducted in 800 healthy males, subjects with serum 25(OH)D concentrations < 40 nmol/L had significantly more days of absence from duty due to respiratory infection. 60 In a study carried out in 2135 patients with prehospitalization vitamin D measurement, patients with vitamin D < 10 ng/mL had 2.33 times more hospital acquired bloodstream infection. 61 There is also data regarding the association of viral infection and vitamin D deficiency. Both conditions occur more frequently in winter time and intervention on vitamin D deficiency may improve outcome of respiratory infections. 62 In a post-hoc analysis of Randomised Evaluation of Calcium and/OR vitamin D (RECORD) trial, conducted in 5292 patients, patients received either placebo or 800 IU vitamin D and there was tendency of fewer self-reported infections and antibiotic usage but this was not statistically significant. 63 There are few data to suggest that vitamin D may be associated with frequent exacerbations, colonization and bacterial eradications. 35, 36, 53 In a study originally designed to investigate the effect of daily azithromycin on COPD exacerbations, Kunisaki et al. did not find an association of vitamin In a recent longitudinal study, 77% of the COPD patients coming from a Primary Care setting showed vitamin D deficiency. After adjustment for effects of supplementation and stratification according to the level of vitamin D, there was no difference in exacerbation rate and mortality. 67 More recently 426 COPD patients in Norway was followed for 3 years and the relation with the vitamin D level at the study entry and exacerbation rate and mortality was evaluated and found no significant effect. 68 In an Italian study conducted in 97 COPD patients, vitamin D deficiency was independently related with frequent exacerbation and hospitalization in the preceding year.
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A very recent meta-analysis showed that low levels of serum vitamin D detected in exacerbated patients compared to stable COPD patients, however vitamin D deficiency was not found to be associated with increased risk of COPD exacerbation. 70 Based on the current data, there is no enough evidence to support the association between vitamin D deficiency and COPD exacerbation.
| Pulmonary function in COPD and vitamin D deficiency
The strongest evidence for a connection between vitamin D deficiency and pulmonary function comes from NHANES III. This cross sectional study showed a strong association between vitamin D levels and forced expiratory flow in one second (FEV 1 ) and forced vital capacity (FVC). There was a 126 ml and 172 ml mean difference in FEV 1 and FVC respectively between the patients with lowest and highest quintile of vitamin D levels. 71 After adjustment for amount of leisure time activities, milk and antioxidant intake and dietary intake, the differences were less but still significant, at 106 and 142 ml, respectively. When inactive patients excluded from the analysis the difference was still significant: 127 ml in FEV 1 (10, 70) . Jansens et al. showed that vitamin D deficiency was more common (60%-77%) in patients with COPD 35 compared with smokers with normal lung function (31%). The serum vitamin D level was independently correlated with FEV 1 (r 5 0.28, P < .0001). Additionally, vitamin D level was 25% lower in homozygous carriers of rs7041 at-risk T allele (P < .0001). Logistic regression analysis showed that people with rs7041 T allele exhibited a 2.11 times greater risk for COPD. 72 In a longitudinal nested, case-control study in the Lung Health Study 3 cohort, baseline 25(OH) D levels were compared between rapid and slow lung function decliners. There was no significant difference in baseline 25(OH)D levels (25.0 vs. 25.9 ng/mL) between rapid and slow decliners. 73 Vitamin D insufficiency and deficiency were common among continuous smokers with established mild to moderate COPD, however; the baseline 25(OH) D levels were not predictive of subsequent lung function decline. 73 In the Norway cohort, vitamin D deficient patients (<10 ng/mL) had greater FEV 1 decline when compare the others. 68 In a cross sectional study of COPD patients in the UK, a relationship was found between dietary vitamin D intake and FEV 1 , FEV 1 /FVC and a negative association with vitamin D intake and the presence of COPD. However, the same study failed to show any association between serum level of vitamin D and FEV 1 or a positive association with serum vitamin level and presence of COPD. VDR genotypes did not have any relationship with lung function. 74 In another study in 433 COPD (GOLD grade II-IV) and 325 controls showed that COPD was associated with lower levels of vitamin D (r 5 24.34, P 5 .001) and COPD patients had more than two times risk of being vitamin D deficient (OR 52.32, P5 .001), after adjusting for sex, age, body mass index (BMI), smoking, comorbidities and season. In logistic regression models, the determinants of vitamin D deficiency were identified as being worse GOLD grade for airflow limitation, obesity and current smoking. 18 In a post hoc analysis, in 498 patients drawn from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) cohort, vitamin D level was found to correlate with FEV 1 (P 5 .01) and computerized tomography (CT) emphysema score (P < .01), VDBP did not show a correlation, although Vitamin D level was inversely correlated with VDBP (P 5 .01). In the same study, Vitamin D level correlated with bronchodilator response, 6 minute walk distance and Clara cell protein-16. 75 Most recently, in the Copenhagen City Heart Study and Copenhagen General Population Study, it was shown for the first time that low plasma level of 25(OH)D was associated with a faster decline of FEV 1 (OR: 2.30 and 3.06 for the two populations respectively). 55 As a summary most of the studies are supported that there is a positive relation with vitamin D level and lung functions. The results of these observational vitamin D studies on pulmonary function in COPD are shown in Table 2 . Vitamin D in the elderly is associated with reductions in not only bone mineral density but in type 2 muscle fibers.
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Observational studies report an association between vitamin D, muscle function and physical performance in the elderly. In a study conducted in Longitudinal Aging Study Amsterdam, subjects were asked if they have any difficulty in daily life physically and in the older patients, vitamin D deficiency was found to be associated with an increase in limitations at 3 years. 80 Korean National Health and Nutrition Examination Survey included 2258 men and 3005 women over 50 years showed an inverse association with vitamin D level and sarcopenia in women. 81 In a meta-analysis conducted in 2009 with 8 randomised controlled trials in 2426 subjects, daily vitamin D supplementation with 700-1000 IU was found to reduce the fall risk 19%. The blood level of vitamin D was found over 60 nmol/L to reduce the risk. 82 Another meta-analysis on 45 782 people, mainly elderly females, found a significant reduction in falls with vitamin D supplementation in addition to calcium administration. The effect was not related to the dose or form of vitamin D supplementation. The quality of evidence was low to moderate. 83 Although the mechanisms are not fully elucidated, skeletal muscle weakness is a crucial feature and independent parameter of mortality in COPD. 84 In COPD patients, 18%
to 36% of patients present with detriment of muscle mass, which is responsible for weight loss in 17% to 35% of patients. The estimated overall prevalence of skeletal muscle weakness in COPD is 20%-30%. [85] [86] [87] Several studies assessed the association with vitamin D and muscle dysfunctions in COPD. In a study that examined the association of the VDR gene and quadriceps strength, FokI common variants in the VDR gene were associated with quadriceps strength in both COPD and control subjects, whereas the BsmI polymorphism was associated with muscle strength only in COPD subjects. 88 Ferrari et al. also demonstrated that maximal exercise capacity and carbon monoxide transfer capacity were positively correlated with serum vitamin D level. 89 In a post-hoc subgroup analysis of a randomized trial on vitamin D supplementation, muscle strength and exercise performance were evaluated in 50 COPD patients before and 3 months after initiating 100 000 IU/monthly vitamin D or placebo. Patients receiving vitamin D had significantly larger improvements in inspiratory muscle strength and maximal oxygen uptake. Improvements in quadriceps strength and six-minute walking distance were not significantly different from the results in the placebo group. 90 In another study Lange et al. found that vitamin D deficient (<25 nmol/L) patients had a worse outcome from a rehabilitation programme, with more dropouts and worse medical condition. 78 Bjerk et al. performed a 6-week vitamin D supplementation trial on COPD patients to test whether 2000 IU daily vitamin D had any effect on physical performance measured using the Short Physical Performance Battery compared to placebo. There was no discernible effect on outcome. 91 In another recent study, in 104 COPD patients and 100 age-and sexmatched controls, serum vitamin D level were found to be same in both groups; vitamin D level was significantly correlated with muscle strength in controls but not in COPD. The authors suggested that vitamin D resistance may occur in COPD. 92 As a summary, there seems to be no conclusive results from the existing studies that shows firmly that there is an association between vitamin D level and a benefit of vitamin D supplementation and muscle functions in COPD population. Presumably, the studies were underpowered to answer that specific questions and well-design studies are needed.
| Prevention and treatment of vitamin D deficiency
COPD has systemic consequences or associations that affect patients' health 93 ; Cardiovascular disease and cancers are the most significant comorbidities seen in COPD with an impact on mortality. 94 Low levels of vitamin D are associated with common comorbidities of COPD 15, 16, 71, 72 and this has led to an interest in whether vitamin D supplementation would have any beneficial effect on mortality and other outcome parameters. A recent meta-analysis of randomized control trials showed that vitamin D supplementation was associated with decreased total mortality rate. 95 Zittermann et al.
showed that this was not a linear association and the optimal dose range is between 75 nmol to 87.5 nmol/L. 96 Although the best way to produce vitamin D is sunlight exposure, there are limitations and hazardous associated with this, so nutritional supplementation is receiving much attention. There is no worldwide consensus on optimal dietary intakes and optimal levels of serum vitamin D level. 13 It also recommends vitamin D supplementation for fall prevention, but does not recommend its use for any noncalcemic effects, such as reducing cardiovascular risks or death. 13 Despite these recommendations, many papers have been published to intervene vitamin D deficiency for various outcomes including prevention of osteoporosis, fractures and falls, prevention and treatment of infections, prevention of COPD exacerbations. The papers have also tested different targets of 25 (OH)D blood levels with different dosing and treatment interval. We summarized some of those evidence as follows.
Evidence showed that vitamin D supplementation reduced nonvertebral fractures and improved muscle strength was suggestive but not clearly convincing. 99 Additionally, in a recent study lowest quintile and the highest quintile of blood vitamin D level (<36 nmol/L and >72 nmol/L) showed the highest risk of fracture indicating the 60 to 72 nmol/L as the best target for blood level in elderly men. 100 Therefore, the existing target for calcium hemostasis (50-75 nmol/L) is also valid for reducing fall and fracture risk with the current data. 25 In regards with infectious outcomes, a higher blood level of vitamin is required. The Australian Health Authority recommends 95 nmol/L serum 25 (OH)D concentration for prevention of respiratory infection. 101 Vitamin D supplementation has promising effects in several studies on prevention of respiratory infection however there is inconsistency causing difficulties to draw a definitive conclusion. 102 In a recent study, an addition of intermittent bolus-dose vitamin D3 supplementation to a daily low-dose regimen did not enhance protection against acute respiratory infection in older adults and their carers The intervention was associated with increased risk and duration of upper respiratory infection. Large intermittent oral boluses of vitamin D supplement has been hypothesised to dysregulate vitamin D metabolism in extrarenal tissues by causing inappropriately low 1-alpha-hydroxylase activity coupled with inappropriately high 24-hydroxylase activity, which may limit local concentrations of the active vitamin D metabolite 1,25-dihydroxyvitamin D. It has also been suggested that "parent vitamin D3" (cholecalciferol) may itself play an important physiological role since the half-life of this compound is only 24 h, daily dosing with 400 IU would have caused sustained elevation of cholecalciferol levels, whereas dosing at 2-month intervals would not have. [103] [104] [105] In a very recent study, Zittermann et al. suggested proctective effect of vitamin D supplementation for acute respiratory infection for individuals with deficit or insufficient vitamin D. They recommended daily administration of 1000 IU daily vitamin D instead of high dose bolus administration starting with early autumn to cover winter time. 106 COPD is the main focus of this review. There are two large studies on COPD and vitamin D supplementation: Lehouck et al. conducted a one year, single-center, randomized, double-blind, placebo-controlled study to test the effect of monthly 100,000 IU vitamin D supplementation on exacerbation rates in 182 COPD patients. It increased the serum vitamin D level when compared to placebo, but the median time to first exacerbation, exacerbation rates, FEV 1 , hospitalisation, quality of life and death did not differ between groups. However, a post-hoc analysis carried out in 30 patients with severe vitamin D deficiency ( 10 ng/mL) at baseline showed a significant reduction in exacerbations in the vitamin D group. has been conducted to evaluate several COPD related outcomes. 240 COPD patients were randomly allocated to the vitamin D3 and placebo groups. Vitamin D3 supplementation did not affect time to first moderate or severe exacerbation or time to first upper respiratory infection. Prespecified subgroup analysis showed that vitamin D3 was protective against moderate or severe exacerbation in participants with baseline serum 25-hydroxyvitamin D concentrations of less than 50 nmol/L. Baseline vitamin D status did not modify the effect of the intervention on risk of upper respiratory infection. 108 
| C ON CLUSI ON
Both vitamin D and COPD are worldwide health problems. Vitamin D has been known for a long time to be related with bone and muscle health. However, evidence has accumulated that more attention should be paid to its noncalcemic effects, particularly in chronic disease. In COPD, research to date has resulted in conflicting data and without concrete conclusions. We do not know if vitamin D deficiency is a risk factor for COPD onset or progression even though vitamin D deficiency is very prevalent in COPD patients and higher than non-COPD population. There might be common risks factors for COPD severity and vitamin D deficiency. More severe COPD patients tend to stay home and are physically less active, which are also risk factors for vitamin D deficiency. Vitamin D has been shown to be related to many conditions associated with COPD, such as osteoporosis, muscle weakness, infection and cardiovascular disease. This may provide a beneficial effect in preventing falls in addition to preventing and treating osteoporosis. We lack any firm data to recommend higher doses of supplementation to prevent COPD onset, progression and exacerbation. There is more future research to test whether vitamin D supplementation has any beneficial effects on COPD associated comorbidities and overall quality of life and mortality.
